Leo Polosajian, MD
Clinical Cardiac Electrophysiology · Reseda, CANPI 1174664783
Payments from drug & device makers
What this record shows
This record is dominated by other: $113,750 of the $168,983 with a category attached, or 67.3%. Angiodynamics, Inc. accounts for 69.1% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $37,665, 4.5 times the $8,292 reported in 2019.
Across 1,362 payments — averaging $124.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$117K
- Abbott$17K
- AstraZeneca$13K
- Medtronic$2K
- Novartis$2K
- Amgen$2K
- plus $16K from 54 others
Across 59 payments — averaging $1593.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$92K
- Novartis$2K
What the payments were for
- Consulting fees$6,3874%
- Speaking & faculty fees$12,0757%
- Travel & lodging$3,1782%
- Food & beverage$33,23020%
- Education$3630%
- Other$113,75067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$114,254
- FARXIGA$12,204
- Allure CRT Pacemaker$2,794
- Confirm Rx$1,970
- AVEIR$1,841
- Accent Pacemaker$1,813
- AngioVac$1,781
- Barostim Neo System$1,259
- Quadra Assura CRT Defibrillator$562
- AlphaVac$555
- GALLANT$460
- ENSITE$387
- Micra$351
- Merlin Connectivity and Remote$342
- LINQ II$319
- WATCHMAN FLX$289
- OPTIMIZER$251
- Edwards SAPIEN 3 Transcatheter Heart Valve$216
- ATRICLIP LAA EXCLUSION SYSTEM$197
- SYNERGY ABLATION SYSTEM$197
How this compares
$168,983 in reported general payments places this provider in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,409 | $1,124,487 |
| EntrestoSacubitril/Valsartan | 1,163 | $968,275 |
| Repatha SureclickEvolocumab | 666 | $393,021 |
| FarxigaDapagliflozin Propanediol | 332 | $292,507 |
| AdempasRiociguat | 14 | $193,695 |
| XareltoRivaroxaban | 193 | $181,514 |
| JardianceEmpagliflozin | 109 | $99,858 |
| Praluent PenAlirocumab | 164 | $93,985 |
| BrilintaTicagrelor | 170 | $93,414 |
| OzempicSemaglutide | 68 | $63,923 |
| JanuviaSitagliptin Phosphate | 91 | $61,141 |
| MultaqDronedarone Hcl | 52 | $54,021 |
| DapagliflozinDapagliflozin Propanediol | 93 | $53,229 |
| VerquvoVericiguat | 54 | $41,786 |
| Fenofibrate | 239 | $33,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,034 | $1,124,4871,409 claims |
| NovartisEntresto | $1,902 | $968,2751,163 claims |
| AstraZenecaFarxiga, Brilinta, Nexium | $12,812 | $394,584523 claims |
| BayerAdempas | $1,550 | $193,69514 claims |
| Johnson & JohnsonXarelto | $668 | $181,514193 claims |
| MerckJanuvia, Verquvo, Janumet | $802 | $121,406178 claims |
| Boehringer IngelheimJardiance, Jentadueto Xr | $868 | $106,201121 claims |
| Novo NordiskOzempic | $283 | $63,92368 claims |
| Sanofi-aventis U.S. LLCMultaq | $718 | $54,02152 claims |
| AbbVieLinzess | $26 | $14,81820 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $50 | $6,91121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Reseda
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
- Rajesh BankerNewport Beach$538K
- Rahul DoshiLos Angeles$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.